February 25, 2015
Press release
Mitsubishi Tanabe Pharma Corporation

Medicago Develops Alternative Production Process for Ebola Antibodies
Contract concluded with U.S. government
Osaka, Japan, February 25, 2015―Mitsubishi Tanabe Pharma Corporation (President andRepresentative Director: Masayuki Mitsuka) and Medicago Inc., (Head Office: Quebec, Canada; President
and CEO: Andy Sheldon) have announced the signing of a contract with the Biomedical Advanced
Research and Development Authority (BARDA), a public institution within the U.S. Department of Healthand Human Services. The contract is for an alternative production process for Ebola antibodies that uses
Medicago’s plant-based protein production and refining technologies.
Ebola hemorrhagic fever has become a major threat to international society, but there are not yet any
effective treatment methods, drugs, or vaccines, and new treatment methods have been long-awaited. In
this setting, ZMapp™, a drug that is under development by Mapp Biopharmaceutical Inc. (Head Office: SanDiego, U.S.), has been the focus of attention as a means of treating Ebola hemorrhagic fever. Medicago
has proprietary technologies for the plant-based production, extraction, and refining of proteins, and thosetechnologies have been highly evaluated by the U.S. government. Medicago has studied alternative
production processes for the Ebola antibodies used in ZMapp™, and moving forward Medicago will work todevelop processes with focus on increased productivity and to produce of investigational antibodies forpre-clinical trials.

〈〈For Details, Contact the Following Section〉〉
Corporate Communications Department
Tel +81-6-6205-5211

PRESS RELEASEMEDICAGO AWARDED A CONTRACT BY THE U.S. DEPARTMENT OF HEALTH AND HUMANSERVICES TO EXPLORE ALTERNATE PRODUCTION METHODS FOR EBOLA ANTIBODIESQUEBEC, CANADA (February 24, 2015) – Medicago, a leading company in the development andproduction of plant-based vaccines and therapeutics, announced today that it has received a taskorder from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S.
Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies(mAbs) with expected performance comparable to that of ZMapp™, from Mapp
Biopharmaceutical.
Medicago will manufacture the antibodies, two of which were discovered by the Public HealthAgency of Canada in its Quebec City, Canada facility for a study in non-human primates (NHP).
This order is the result of a Task Order Request (TOR) that was solicited by BARDA on December 22,
2014. It is part of the indefinite Delivery/Indefinite Quantity (ID/IQ) contract between Medicago
and the Defense Advanced Research Projects Agency (DARPA).
Joining the global efforts against Ebola
Medicago is pleased to join the international efforts against the Ebola virus. Medicago intends todemonstrate the comparable performance of its anti-Ebola antibodies to ZMappTM.
"Medicago’s production platform has demonstrated its important potential for responding tointernational emergencies and pandemics when it produced candidate vaccines for H1N1
in 2009 and H7N9 in 2013," said Andy Sheldon, Medicago’s CEO. "As governments aroundthe world continue to face health threats like pandemic strains of influenza and Ebola viruses,
we believe that Medicago can make a major contribution to rapid response, surge
capacity and stockpiles across the globe."
Preliminary results have shown that Medicago’s technology can rapidly produce anti-Ebola
antibodies with high yields, thereby potentially boosting production volumes and worldwide
supply.
In accordance with U.S. Federal Acquisition Regulations (FAR 16.505 (b)(1)), this TOR allowed all four
awardees of the DARPA ID/IQ contracts to compete. Medicago’s ID/IQ contract was awarded inDecember 2012.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines andtherapeutic proteins to address a broad range of infectious diseases worldwide. Thecompany is committed to providing highly effective and competitive vaccines andtherapeutic proteins based on its proprietary Virus-Like Particles (VLPs) and manufacturing
technologies.
This technology has the potential to offer vaccines and therapeutics with speed and costadvantages over competitive technologies, enabling the development of products fortesting within approximately one month after the identification and reception of genetic
sequences. This production time frame has the potential to rapidly vaccinate or treat
populations and supply large volumes of product to the global market.
//www.medicago.com/
About BARDA
The Biomedical Advanced Research and Development Authority (BARDA), within the Office
Of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department Of
Health and Human Services, provides an integrated, systematic approach to thedevelopment and purchase of the necessary vaccines, drugs, therapies, and diagnostic
tools for public health medical emergencies. //www.medicalcountermeasures.gov/
For more information

Media Contact :TACT Intelligence-conseil
Michelle O’Brodovich
Cell: 418-933-3476
mobrodovich@tactconseil.ca
For inquiries regarding BARDA:
ASPR Public Affairs, Director
Gretchen Michael
Phone: 202-205-8114
Gretchen.Michael@hhs.gov